- Home
- CIVB vs AUTL Comparison
CIVB vs AUTL Comparison
Compare CIVB & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CIVB | AUTL |
|---|---|---|
| Founded | 1884 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 571.6M | 532.3M |
| IPO Year | 2012 | 2025 |
Fundamental Metrics
Financial Performance| Metric | CIVB | AUTL |
|---|---|---|
| Price | $27.40 | $2.24 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 4 |
| Target Price | ★ $26.60 | $8.50 |
| AVG Volume (30 Days) | 143.7K | ★ 2.7M |
| Earning Date | 04-22-2026 | 05-14-2026 |
| Dividend Yield | ★ 2.90% | N/A |
| EPS Growth | ★ 31.34 | N/A |
| EPS | ★ 1.41 | N/A |
| Revenue | ★ $19,023,000.00 | $10,120,000.00 |
| Revenue This Year | $14.88 | $80.32 |
| Revenue Next Year | $5.99 | $53.96 |
| P/E Ratio | $19.44 | ★ N/A |
| Revenue Growth | N/A | ★ 496.00 |
| 52 Week Low | $19.84 | $1.18 |
| 52 Week High | $29.97 | $2.58 |
Technical Indicators
Market Signals| Indicator | CIVB | AUTL |
|---|---|---|
| Relative Strength Index (RSI) | 45.65 | 56.32 |
| Support Level | $27.00 | $1.37 |
| Resistance Level | $29.31 | $2.43 |
| Average True Range (ATR) | 0.53 | 0.12 |
| MACD | -0.05 | -0.04 |
| Stochastic Oscillator | 50.00 | 33.33 |
Price Performance
Historical ComparisonAbout CIVB Civista Bancshares Inc.
Civista Bancshares Inc is a financial holding company. Operating through its subsidiary, it engages in the business of community banking. Its business activity involves collecting customer deposits, making loans, purchasing securities, and offering trust services to its clients. The company's loan portfolio includes commercial and agricultural, commercial real estate-owner occupied, commercial real estate non-owner occupied, residential real estate, real estate construction, and consumer loans. The majority of its revenues are derived from the interest and fees gained on loans.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.